Glenmark Stock Price in Green After Company Launches TEVIMBRA in India

Mumbai, 24 June 2025: Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK, BSE: 532296) announced the launch of its advanced immunotherapy drug TEVIMBRA® (tislelizumab) in India, marking its first step into the country’s growing immuno-oncology segment. The drug’s approval by the Central Drugs Standard Control Organization (CDSCO) was revealed through an exchange filing early this morning, which was quickly followed by a modest rise in the company’s share price.

As of 10:12 AM IST on 24 June, Glenmark Pharmaceuticals Ltd. was trading at ₹1,687.10, up ₹2.30 or 0.14% for the day. The stock opened at ₹1,691.00 and reached an intraday high of ₹1,699.00 before dipping to a low of ₹1,674.60. The company’s market capitalisation stood at ₹47,670 crore with a P/E ratio of 45.46. Glenmark’s 52-week range spans from ₹1,199.30 to ₹1,830.95, reflecting its strong performance over the year.

Stock Climbs Over 0.5% Post Launch News

Glenmark shares showed a positive early reaction to the announcement, with modest but steady gains observed:

The stock moved within a narrow range early in the session before inching upward, reflecting investor confidence in Glenmark’s strategic expansion into oncology.

TEVIMBRA® Set to Strengthen Glenmark’s Cancer Care Offerings

TEVIMBRA®, developed by BeOne Medicines (formerly BeiGene), is a next-generation anti-PD-1 monoclonal antibody. It is now approved in India for:

• First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) when combined with chemotherapy
• Second-line monotherapy for NSCLC and esophageal squamous cell carcinoma (ESCC)

India faces a rising burden of cancer cases, with NSCLC accounting for over 80% of all lung cancer diagnoses and ESCC being the most common form of oesophageal cancer in the country. Glenmark’s launch positions it to meet urgent oncological needs with globally proven treatment options.

Leadership: Glenmark Enters a New Phase in Oncology Mission

Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd., remarked,

“With the launch of TEVIMBRA, Glenmark is delivering on its commitment to transform cancer care in India by making globally benchmarked immunotherapies more accessible.”

He further highlighted that Glenmark’s oncology vision is entering a pivotal phase, focusing on innovation and science-led approaches that make a tangible difference to patients’ lives.

Global Success of TEVIMBRA® Adds Credibility to Indian Rollout

TEVIMBRA® has already been approved in 46 countries and administered to over 1.5 million patients globally. Its clinical development programme includes:

• 70 active trials across 35 countries
• Nearly 14,000 enrolled patients
• 21 registration-enabling studies globally

What sets TEVIMBRA® apart is its targeted mechanism, which enhances T-cell activity while minimising off-target immune reactions, positioning it as a strong contender in the global immuno-oncology landscape.

About Glenmark: A Rising Force in Oncology Innovation

Glenmark Pharmaceuticals is a research-driven global pharma company with a strong presence in branded, generic, and over-the-counter (OTC) medications across respiratory, dermatology, and oncology therapies. With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, the company ranks:

• Among the Top 100 global biopharmaceutical firms by sales
• Within the Top 50 in the generics and biosimilars space

The launch of TEVIMBRA® marks a significant milestone in Glenmark’s ambition to become a key oncology player in both domestic and international markets.

REF: https://nsearchives.nseindia.com/corporate/GLENMARK_24062025094433_PR24062025_signed.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations